MarginsXMarginsX
Home › Markets › Health Care › NVS

Novartis AG (NVS)

NVS trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$160.20
-0.19% on the day
Market cap
$305.7B
Mega cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerNVS on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountrySwitzerland
IPO yearNot reported by the screener
SEC CIK0001114448
SEC industry codePharmaceutical Preparations
Incorporated inSwitzerland

Financials

Foreign filer: no machine-readable annual figure in SEC data.

Warning signs

Cash runway
Cash-flow positive
$11.4B cash at December 31, 2025
Share count, 1 year
-3.4%
2024-12-31 to 2025-12-31 · -10.0% over 3 years
Going-concern doubt
No
20-F filed February 4, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-02-04
Cash and burn$11.4B cash; operating cash flow $4.8B a quarter.Report 2025-12-31
Shares outstanding1,908,151,679 (2025-12-31); 1,975,089,248 a year earlier; 2,119,609,057 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 4 424B5 takedownsLatest 2026-11-10
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG AG, Basel, SwitzerlandPCAOB Form AP 2026-03-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filed$14.0B$19.1B$11.4B$28.7BNeeds four quarters20-F 2026-02-04
FY 2024
2024-12-31
Not filed$11.9B$17.6B$11.5B$24.7BNeeds four quarters20-F 2026-02-04
FY 2023
2023-12-31
Not filed$14.8B$14.5B$13.4B$20.6BNeeds four quarters20-F 2026-02-04
FY 2022
2022-12-31
Not filed$7.0B$14.2B$7.5B$22.5BNeeds four quarters20-F 2025-01-31
FY 2021
2021-12-31
Not filed$24.0B$15.1B$12.4B$25.5BNeeds four quarters20-F 2024-01-31
FY 2020
2020-12-31
Not filed$8.1B$13.7B$9.7B$28.5BNeeds four quarters20-F/A 2023-05-15
FY 2019
2019-12-31
Not filed$11.7B$13.6B$11.1B$22.4BNeeds four quarters20-F 2022-02-02
FY 2018
2018-12-31
Not filed$12.6B$14.3B$13.3B$25.7BNeeds four quarters20-F 2021-01-26

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-11-10
Latest annual report20-F2026-02-04
Latest quarterly / interim
FORM 6-K
6-K2026-11-12

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.3%
1 month+12.7%
3 months+5.8%
Year to date+16.4%
1 year+21.7%
From 52-week high-4.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
AZNAstraZeneca PLC$184.02-0.23%$285.4B
MRKMerck & Company Inc. Common Stock (new)$144.46-2.23%$356.1B
ABTAbbott Laboratories$107.45-0.99%$186.1B
NVONovo Nordisk A/S$41.60-0.07%$184.2B
ABBVAbbVie Inc.$294.55-0.16%$520.7B
PFEPfizer Inc.$28.86-0.10%$164.5B
JNJJohnson & Johnson$282.55-1.12%$680.2B
VRTXVertex Pharmaceuticals Incorporated$537.79-0.15%$136.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier